Lead idea
GLP-1 drugs pose a long-term terminal risk
The hosts argued that GLP-1 weight-loss drugs represent a significant, non-transitory risk to McDonald's by chemically reducing appetite and altering food cravings. Argued on We Study Billionaires - The Investors Podcast Network’s “TIP858: McDonald's ($MCD): Generational Compounder in Historical Drawdown w/ Daniel Mahncke & Shawn O'Malley”, aired 5 November 2026. The case made was that these drugs, now used by over 10% of US adults, work by slowing digestion and dampening dopamine-driven reward signals from foods like those McDonald's sells.